中国中药(00570)10月21日盘中股价一度暴跌44.5%,报2.12港元,创下近11年新低。截至发稿,股价跌幅收窄至34.3%,报2.47港元,全日成交金额逾13亿港元。
暴跌的直接导火索是,中国中药上周五公布国药集团共裕通过计划安排方式将公司私有化的相关建议失效。公司公告称,要约人国药集团共裕未能在最后期限前获得所需的境外直接投资批准等先决条件,因此私有化建议于10月18日失效,公司将继续在港交所保持上市地位。
这意味着此前国药集团以每股4.6港元的高溢价收购中国中药私有化的计划宣告流产,对大股东而言是一次融资失利,对投资者而言也无缘分享溢价退市收益。对于中国中药公司而言,直接导致大笔融资计划落空,未来发展也将受到一定制约。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.